close

Agreements

1 228 229 230 231 232 237
Number of results: 4727

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-05-09 Kancera (Sweden) Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center (USA)

R&D

Cancer - Oncology R&D agreement
2011-05-09 Heptares Therapeutics (UK) Shire Pharmaceuticals (UK) novel adenosine A2A antagonist CNS diseases

Licensing
Development
Commercialisation

CNS diseases Licensing agreement
2011-05-05 Almirall (Spain) Nycomed (Switzerland) roflumilast chronic obstructive pulmonary disease (COPD)

commercialisation

Respiratory diseases Commercialisation agreement
2011-05-04 Oxford Biomedica( UK) Pfizer (USA- NY) therapeutic products which target the Oxford Biomedica’s proprietary 5T4 tumour antigen

licensing

Cancer - Oncology Licensing agreement
2011-05-04 Algeta (Norway) Affibody (Sweden) Affibody® molecules and Albumod™ for two targets within the oncology field, HER2 and PDGFR-Beta

Licensing
Collaboration

Cancer Oncology Licensing agreement
2011-05-04 Cenix Biosciences (Germany) Janssen Pharmaceutica (J&J-USA) in vivo siRNA delivery technology

R&D
Licensing

CNS diseases R&D agreement
2011-05-04 Debiopharm (Switzerland) Yale University (USA) Debio 1036

licensing
development
commercialisation

Autoimmune diseases - Inflammatory diseases Licensing agreement
2011-05-04 Angel Biotechnology (UK) Pathfinder Cell Therapy (USA) newly discovered mammalian cell type capable of stimulating damaged tissues to regenerate

manufacturing
production

Production agreement
2011-05-02 Dyadic (USA) Engen Bio (USA) Sanofi Pasteur (France) undisclosed

R&D

R&D agreement
2011-04-28 Flamel Technologies (France) Undisclosed specialty pharmaceutical company two molecules for pain indications pain

Licensing

CNS diseases Licensing agreement
2011-04-27 Affitech (Denmark) Cancer Research Technology (UK) therapeutic antibodies that recognize and block the function of CCR4* AT008 program solid tumors

licensing
collaboration

Cancer - Oncology Licensing agreement
2011-04-27 Affitech (Denmark) University of Texas Southwestern Medical Center (USA) AT001/r84

Collaboration

Collaboration agreement
2011-04-27 Beactica (Sweden) Janssen Research & Development - J&J (Belgium-USA) Sprint™ undisclosed

R&D
collaboration
services

undisclosed R&D agreement
2011-04-26 Vivalis (France) SC World (Japan) Toyama Prefecture (Japan) high-throughput screening (HTS) single-cell antibody discovery technology

Licensing

Licensing agreement
2011-04-26 Karo Bio (Sweden) Alkem (India) eprotirome heterozygous familial hypercholesterolemia

collaboration

licensing

Cardiovascular diseases - Genetic diseases - Metabolic diseases Licensing agreement
2011-04-26 Kuros Biosurgery (Switzerland) Baxter (USA) KUR-111, KUR-113, KUR-115

licensing

Traumatology Licensing agreement
2011-04-26 Rhenovia Pharma (France) Sodiaal-Candia (France)

R&D

R&D agreement
2011-04-21 Iris Pharma (France) OPIA Technologies (France) Eyeprim® device

Licensing
Development

Ophtalmology Licensing agreement
2011-04-19 Lonza (Switzerland) ORGANOBALANCE (Germany) products containing a probiotic Lactobacillus strain

Licensing

Nutrition Licensing agreement
2011-04-19 Medigene (Germany) Triton Pharma (Canada) Veregen® ointment (made from the extract of green tea leaves - catechins) External genital warts

licensing
supply
commercialisation

Gynecology - Infectious diseases Licensing agreement